Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug. The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS...